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ORIGINAL ARTICLE
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Medical Center, Lincoln, NE, USA and 5Scleroderma Research Centre, Leeds Institute of Molecular Medicine, LMBU, University
of Leeds, Leeds, UK
Desmoglein-2 (Dsg2) is a desmosomal cadherin that is
aberrantly expressed in human skin carcinomas. In addition
to its well-known role in mediating intercellular desmoso-
mal adhesion, Dsg2 regulates mitogenic signaling that may
promote cancer development and progression. However, the
mechanisms by which Dsg2 activates these signaling
pathways and the relative contribution of its signaling and
adhesion functions in tumor progression are poorly under-
stood. In this study we show that Dsg2 associates with
caveolin-1 (Cav-1), the major protein of specialized
membrane microdomains called caveolae, which functions
in both membrane protein turnover and intracellular
signaling. Sequence analysis revealed that Dsg2 contains
a putative Cav-1-binding motif. A permeable competing
peptide resembling the Cav-1 scaffolding domain bound to
Dsg2, disrupted normal Dsg2 staining and interfered with
the integrity of epithelial sheets in vitro. Additionally, we
observed that Dsg2 is proteolytically processed; resulting in
a 95-kDa ectodomain shed product and a 65-kDa
membrane-spanning fragment, the latter of which localizes
to lipid rafts along with full-length Dsg2. Disruption of lipid
rafts shifted Dsg2 to the non-raft fractions, leading to the
accumulation of these proteins. Interestingly, Dsg2 proteo-
lytic products are elevated in vivo in skin tumors from
transgenic mice overexpressing Dsg2. Collectively, these
data are consistent with the possibility that accumulation of
truncated Dsg2 protein interferes with desmosome assem-
bly and/or maintenance to disrupt cell–cell adhesion.
Furthermore, the association of Dsg2 with Cav-1 may
provide a mechanism for regulating mitogenic signaling and
modulating the cell-surface presentation of an important
adhesion molecule, both of which could contribute to
malignant transformation and tumor progression.
Oncogene (2012) 31, 1636–1648; doi:10.1038/onc.2011.346;
published online 15 August 2011
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Introduction
Desmogleins are the major transmembrane proteins of
the cell–cell adhesion structures known as desmosomes.
There are four distinct desmoglein genes (Dsg1–4) in
humans, which are expressed in a tissue-type and
differentiation-speciﬁc manner (Garrod et al., 2002;
Cheng and Koch, 2004; Mahoney et al., 2006). Studies
involving Dsg2-null mice revealed that Dsg2 contributes
to embryonic stem cell proliferation, particularly in the
inner cell mass of the developing blastocyst (Eshkind
et al., 2002). Dsg2 is aberrantly expressed in select
epithelial malignancies, including squamous cell carci-
nomas (Harada et al., 1996; Kurzen et al., 2003;
Biedermann et al., 2005). Similarly, genetic proﬁling of
prostate cancer cell lines showed increased expression of
Dsg2 in a metastatic cell line, as compared with its non-
metastatic syngeneic precursor cell (Trojan et al., 2005).
Dsg2 expression is also upregulated in squamous cell
carcinoma cell lines in comparison with cultured
keratinocytes (Scha¨fer et al., 1994; Harada et al., 1996;
Denning et al., 1998). We recently showed that Dsg2 is
highly expressed in malignant skin carcinomas, includ-
ing squamous cell carcinomas, basal cell carcinomas,
sweat and sebaceous gland carcinomas, and adenocar-
cinomas (Brennan and Mahoney, 2009). Collectively,
these results support a role for Dsg2 in epithelial cell
growth, survival and malignant transformation. How-
ever, the mechanisms by which Dsg2 activates these
signaling pathways and promotes tumor formation are
unknown.
Caveolins are a family of hairpin-like, palmitoylated,
integral membrane proteins that oligomerize and bind to
cholesterols and sphingolipids to form specialized areas
of the membrane distinct from the clathrin-coated pits.
The caveolins form ﬂask-shaped invaginations of 50–
100 nm in diameter called caveolae (Severs, 1988). There
are three caveolin isoforms: Cav-1 (a and b), Cav-2 and
Cav-3. Whereas Cav-1 and Cav-2 are ubiquitously
expressed, Cav-3 expression is predominantly restricted
to muscle cells (Scherer et al., 1995; Tang et al., 1996).
Caveolins and caveolae have been implicated as
regulators of key cellular functions, including cholester-
ol transport and homeostasis (Fielding and Fielding,
1995; Smart et al., 1996), endocytosis and endocytic
vesicle trafﬁcking (Schnitzer and Oh, 1996), and cell
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adhesion and apoptosis (Lisanti et al., 1994; Okamoto,
1998; Okamoto et al., 1998; Shaul and Anderson, 1998;
Kurzchalia and Parton, 1999). Speciﬁc cell signals can
be also transmitted through a spatially controlled
organization of cell receptors into the caveolae. Indeed,
the epidermal growth factor receptor has been shown to
stimulate the phosphorylation of Cav-1, thus enhancing
caveolae assembly (Singer and Nicolson, 1972; Severs,
1988; Simons and Toomre, 2000; Orlichenko et al.,
2006). Furthermore, Cav-1 is essential for integrin-
mediated activation of phospatidyl inositol-3-kinase/
AKT (Sedding et al., 2005). Conversely, overexpression
of Cav-1 abrogates anchorage-independent cell survival
(Engelman et al., 1997), and suppresses cell growth (Lee
et al., 1998). Additionally, Cav-1 binds to and inhibits
kinases involved in mitogenic signaling pathways. Cav-1
expression can modulate Wnt/b-catenin/Lef-1 signaling
by regulating the intracellular localization of b-catenin
(Galbiati et al., 2000). Consistent with these ﬁndings,
mounting evidence suggests that diseases associated with
deregulated signaling pathways often result from
aberrant expression or localization of Cav-1. In cancer,
the role for Cav-1 is complex, as it serves both as a
modulator of tumor suppression as well as oncogenesis.
Mutations in the Cav-1 gene have been linked to human
breast cancer, suggesting that loss of Cav-1 function has
a signiﬁcant role in tumor initiation (Chen et al., 2004).
Mice devoid of Cav-1 develop mammary epithelial cell
hyperplasia (Capozza et al., 2003) and are susceptible
toward mammary tumorigenesis (Park et al., 2002). In
the skin, Cav-1-null mice are also more susceptible to
epidermal hyperplasia and skin tumor formation in
response to carcinogens (Capozza et al., 2003).
In this report, we provide strong evidence that Dsg2
interacts directly with Cav-1, and that these interactions
may impact Dsg2 recycling, desmosome dynamics and
cell adhesion; and furthermore, provide a mechanism by
which Dsg2 mediates cell signaling.
Results
Colocalization of Cav-1 and Dsg2
We recently showed that overexpression of Dsg2 in the
epidermis results in hyper-proliferation and the forma-
tion of pre-cancerous papillomas; additionally, Dsg2
transgenic mice are more susceptible to chemical-
induced skin carcinogenesis (Brennan et al., 2007).
Furthermore, Dsg2 overexpression in the skin of these
mice results in the activation of several signaling
pathways directly relevant to epithelial cell proliferation
and survival, notably the phospatidyl inositol-3-kinase/
AKT, MEK/mitogen-activated protein kinase and
nuclear factor-kB pathways. We thus searched for
Dsg2-binding partners that could interact with the
intracellular domain, and potentially lead to the
activation of downstream signaling events. We gener-
ated glutathione-S-transferase (GST) fusion recombi-
nant proteins of the intracellular domains (cytoplasmic
tails) of Dsg1 and Dsg2. The GST fusion proteins were
afﬁnity-puriﬁed by using glutathione–sepharose beads,
and bound proteins were eluted with glutathione elution
buffer according to the manufacturer’s protocol
(Figure 1a). To conﬁrm the identity of the fusion
proteins, we performed western blotting analysis by
using the antibodies H-145 and DG3.10 (Figure 1b). We
note here that there are two commercially available H-
145 antibodies: one recognizes Dsg2 whereas the other,
Dsg3. Throughout this report, we used the Dsg2 H-145.
The antibody DG3.10 recognizes both Dsg1 and Dsg2.
Immunoblot analysis showed that H-145 recognized
only the GST-Dsg2.tail, whereas DG3.10 detected both
GST-Dsg1.tail and the GST-Dsg2.tail.
The GST fusion proteins were used to afﬁnity-purify
proteins from A431 cell lysates. By western blot
analysis, we ﬁrst demonstrated that the desmosomal
protein g-catenin (plakoglobin), but not the adherens
junction protein b-catenin, was able to bind to Dsg1 and
Dsg2 (Figure 1c). It was demonstrated previously that
Dsg3 localizes to lipid rafts (Delva et al., 2008) and here
we identiﬁed Cav-1 as one of several novel Dsg2-binding
proteins. Western blotting of cellular proteins eluted
from the columns demonstrated that Cav-1 (22 kDa)
interacted with Dsg2 and Dsg1, but not GST alone
(Figure 1d).
Next, we performed immunoprecipitation assays to
conﬁrm the Dsg2–Cav-1 interaction. A431 cells were
extracted into detergent-free and Triton X-100 (Tx)-
containing protein fractions, incubated with antibody
10D2 (Keim et al., 2008) and the Dsg2 immunocom-
plexes were pulled down with Protein-A/G. The
precipitated products were immunoblotted with H-145,
to conﬁrm the pull-down of the 160-kDa Dsg2 in the Tx
fraction (Figure 1e). Cav-1 was detected in both
detergent-free and Tx-containing fractions. However,
the detergent-free fraction showed higher levels of Cav-
1, suggesting perhaps that, whereas Cav-1 associated
with both desmosome-bound and desmosome-free
Dsg2, it was more likely to associate with Dsg2 outside
of the desmosomal structure, that is, in lipid rafts. In
summary, these results demonstrate that full-length
Dsg2 binds to Cav-1.
To conﬁrm Dsg2–Cav-1 colocalization at the cell
level, we performed double-labeled immunoﬂuorescence
(IF) and laser-scanning confocal microscopy for Dsg2
(green) and Cav-1 (red) in A431 cells (Figure 2). We did
not expect to see extensive colocalization of Dsg2 and
Cav-1 as desmogleins are predominantly found in
desmosomes and Cav-1 in lipid rafts. Indeed, we
observed the hallmark punctate cell–cell border pattern
for Dsg2, whereas Cav-1 had a diffuse cytoplasmic and
cell-surface staining pattern. However, consistent with
our immunoprecipitation results above, we did observe
some colocalization of Dsg2 with Cav-1 at the
membrane.
Next, we wanted to determine whether Cav-1 and
desmogleins are expressed in similar cell compartments
in normal human epidermis. We performed colocaliza-
tion experiments for Cav-1 and Dsg1/Dsg2 (Supple-
mentary Figure S1). We observed pronounced Cav-1
staining at the cell–cell borders, as well as in the
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cytoplasm of keratinocytes in the basal and the
immediate suprabasal layers, which is in accordance
with the literature (Gassmann and Werner, 2000). In the
same epidermal layers, we observed strong staining of
Dsg1 and Dsg2 using antibody DG3.10. Merged image
showed some colocalization, particularly at the cell–cell
borders (arrows demarcate colocalization). These results
demonstrate that, in human skin, Cav-1 is expressed in
the basal and most immediate suprabasal epidermal
layers where desmogleins could be found. Thus,
consistent with our immunoprecipitation results above,
we observed colocalization of desmogleins with Cav-1
primarily at the plasma membrane. In the hair follicle,
where both Dsg2 and Cav-1 expression levels were high,
we observed strong staining of both Dsg2 and Cav-1 in
cells of the outer root sheath (not shown).
Dsg2 interacts with Cav-1 through the Dsg2 consensus
binding motif and the Cav-1 scaffolding domain
Cav-1’s association with many protein-binding partners
is mediated by a conserved 20-amino-acid domain called
the caveolin-scaffolding domain, located between Asp82
and Arg101 (DGIWKASFTTFTVTKYWFYR) of
Cav-1. This conserved domain binds to several con-
sensus-binding motifs (fXfXXXXf, fXXXXfXXf
and fXfXXXXfXXf; where f are aromatic amino
acids phenylalanine F, tyrosine Y and tryptophan W)
present on signaling molecules (Lisanti et al., 1994;
Okamoto et al., 1998). In some cases, hydrophobic
amino acids are found in the place of aromatic amino
acids, and the binding motifs may also be reversed in
orientation (fXXXXfXf, fXXXXfXXf or
fXXfXXXXfXf). Examination of the Dsg2 amino-
acid sequence revealed a potential Cav-1-binding motif
(776FTDKAASY783) in the cytoplasmic tail domain
(Mahoney et al., 2002; Whittock, 2003) (Figure 3a).
To demonstrate that Dsg2 can associate with the Cav-1
scaffolding domain, we generated a fusion peptide
consisting of the Drosophila antennapedia (AP,
RQPKIWFPNRRKPWKK) homeodomain, and a pu-
tative competing peptide resembling the scaffolding
domain of Cav-1. The AP and AP-Cav-1 peptides are
cell-permeable and are biotinylated at the N-terminus
(Figure 3b). The bioactive Cav-1 fragment, AP–Cav-1,
was previously used to restore Cav-1 bioavailability and
abrogate transforming growth factor-b activation of
cultured human dermal ﬁbroblasts (Del Galdo et al.,
2008). For our study, we reasoned that the peptide
would disrupt the binding of Dsg2 with Cav-1. Thus, we
treated A431 cells with either AP or AP-Cav-1 (5 mM) in
serum-free medium for 1 h, and lysed in a 1% Tx lysis
buffer. Cell lysates were incubated with the anti-Dsg2
antibody 10D2 and precipitated with Protein-A/G–
agarose. The precipitated proteins were resolved by
sodium dodecyl sulfate (SDS)–PAGE and immuno-
blotted using strep-avidin–horseradish peroxidase
(HRP) (Figure 3c). The results showed that anti-Dsg2
pulled down biotinylated AP–Cav-1, but not biotiny-
lated AP alone. These results demonstrate that Dsg2
associates with Cav-1, most likely through the Cav-1
scaffolding domain.
To further assess whether Cav-1 has a role in
maintaining desmosome dynamics, we treated A431
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Figure 1 Cav-1 is a binding partner of desmogleins. (a) Coomasie
staining of puriﬁed GST and GST fusion proteins with intracellular
domains of Dsg1 (GST–Dsg1) or Dsg2 (GST–Dsg2). (b) IB of GST,
GST–Dsg1 and GST–Dsg2 using antibodies H-145 and DG3.10.
H-145 recognized Dsg2 only, whereas DG3.10 recognized both Dsg1
and Dsg2. (c) These fusion proteins were used in a GST pull-down
assay with A431 cell lysates. Whereas A431 cells expressed both
g-catenin and b-catenin, Dsg1 and Dsg2 were able to pull down
g-catenin but not b-catenin. (d) GST pull-down assay with GST,
GST–Dsg1 and GST–Dsg2, and A431 cell lysates, followed by
western blotting for Cav-1. Cav-1 was detected in the pull-down with
Dsg1 and Dsg2 but not GST. (e) Immunoprecipitation assay further
conﬁrms that Dsg2 binds to Cav-1. Tx-soluble (S) and -insoluble (I)
proteins were extracted from A431 cells, and subjected to
immunoprecipitation for Dsg2 (antibody 10D2). The precipitated
products were immunoblotted for Dsg2 (Ab H-145), Cav-1 and
mouse IgG (for equal antibody loading). The panels to the right are
overexposed. I, Tx-insoluble; S, Tx-soluble; Tx, Triton X-100.
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cells with the peptides AP and AP–Cav-1 for 24 h. Cells
were then ﬁxed and immunostained for Dsg2 using 6D8
or DG3.10 (Figure 4). Dsg2 was detected at the cell–cell
border in cells treated with dimethyl sulfoxide or AP
peptide. However, treatment with AP–Cav-1 peptides
dramatically altered the localization of Dsg2 (Figure 4).
We observed diffuse cell-surface staining with loss of the
hallmark punctate cell–cell border staining. We note
here that the haziness of the stainings of the AP–Cav-1-
treated cells is consistent throughout our experiments
with the use of this AP–Cav-1 peptide, and is not due to
errors in photography. In summary, our results thus far
demonstrate that Cav-1 binds to Dsg2, most likely
through the Cav-1-binding domain. Disrupting Cav-1
binding with competing peptides results in profound
changes in the cell-surface localization of Dsg2. We note
here that although it is well established that caveolins
localize to caveolae, structures that are deﬁned by
electron microscopy, as we did not use electron
microscopy in this study, we will refer to these structures
as lipid rafts or membrane microdomains.
Colocalization of Dsg2 to membrane microdomains
To further conﬁrm that Dsg2 binds to Cav-1, and to
determine whether Dsg2 colocalizes with Cav-1 in lipid-
enriched rafts, we performed sucrose density-gradient
fractionation. Lipid rafts are discrete specialized plasma
membrane microdomains (Simons and Ikonen, 1997;
Brown and London, 1998). Owing to their high
cholesterol and sphingolipid content, they can be
isolated based on their detergent insolubility and/or
low buoyant density (detergent-free fractionation). We
used 5–35% discontinuous sucrose-gradient ultracentri-
fugation to isolate caveolin-rich membrane microdo-
mains from A431 cells as described previously (Song
and Dohlman, 1996; Galbiati et al., 2000; Zheng et al.,
2003). Proteins show a light buoyant density because
they are encased in the ‘lipid shells’ of cholesterol and
sphingolipids (Wang et al., 2003). We observed both
Dsg2 and Cav-1 localized to the lighter gradient
fractions of 4–5 (Figure 5a). In addition to Cav-1 and
Cav-2, we detected other lipid raft proteins, including
ﬂotillins (Flo1 and Flo2). Additionally, we also detected
the desmoglein-associated protein, plakoglobin (g-cate-
nin), in the lipid raft fractions. Proteins of the adherens
junction did not co-fractionate under these conditions,
and were primarily in the more dense fractions. Both E-
cadherin and b-catenin were detected in fractions 6–12.
Low levels of b-catenin were also detected in fractions 4
and 5. Interestingly, Dsg2 appeared evenly distributed
throughout all sucrose fractions. We posit that Dsg2
Figure 2 Colocalization of Cav-1 and Dsg2 in epithelial cells. Cultured A431 cells were grown to conﬂuence, ﬁxed and stained for Dsg2
and Cav-1. Confocal microscopy showing colocalization of Dsg2 (green) and Cav-1 (red) in A431 cells. The inset shows a higher resolution
merged image of the cell–cell border area and the arrows demarcate double labeling (yellow) of Cav-1 and Dsg2. We note here that we
used antibody DG3.10, which recognizes both Dsg1 and Dsg2, but as A431 cells do not express Dsg1, the observed staining is Dsg2 only.
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may associate with other caveolae-free membrane
microdomains such as low-density, Triton-resistant
and glycosphingolipid-enriched membrane domains
(Fra et al., 1994). However, as mentioned above,
without using electron microscopy we cannot conclu-
sively ascertain whether Dsg2 resides in caveolae or
simply in microdomains similar to caveolae.
Methyl-b-cyclodextran (MbCD) and ﬁlipin are two
widely accepted treatments for manipulating cholester-
ol-containing domains. Disruption of lipid rafts with
MbCD results in the loss of compartmentalization and
caveolae formation, and shifts Cav-1 out of lipid rafts
and into denser gradient fractions (Furuchi and
Anderson, 1998). Here, we observed a shift of both
Cav-1 and Dsg2 into the higher density fractions 11 and
12 with MbCD treatment (Figure 5a, right panels). A
shift in density fractionation was also observed with
Cav-2, Flo1 and Flo2, and g-catenin. On the other
hand, MbCD did not alter the distribution of b-catenin,
E-cadherin and actin; they all still localized mainly to
the non-lipid raft fractions. Similar results, although to
a lesser extent, were observed when cells were treated
with ﬁlipin (data not shown), which also binds to
cholesterol and alters membrane permeability (Laughlin
et al., 2004).
Interestingly, in untreated control cells, we observed a
band of weaker intensity at approximately 65 kDa that
was recognized by using the Dsg2 antibody in fraction
#4 (Figure 5a, vertical arrow). Treatment with MbCD
resulted in an accumulation of this 65-kDa fragment
(Figure 5a, arrowhead), which was shifted to the high-
density fractions along with the full-length 160 kDa
Dsg2 (arrow). To further characterize the 65-kDa Dsg2
fragment, proteins from sucrose-gradient fractions #4
and #12 of cells both untreated and treated with MbCD
were resolved over SDS–PAGE and immunoblotted
with the Dsg2 antibodies 10D2 and DG3.10 (Figure 5b).
Antibody 10D2, which recognizes the extracellular
domain-1 (EC1) of Dsg2 (Keim et al., 2008; Brennan
and Mahoney, 2009), detected only the 160-kDa full-
length Dsg2 band in both fractions #4 and #12.
Antibody DG3.10, which recognizes epitopes within
the intracellular domain of Dsg2, recognized both the
full-length protein and the truncated 65-kDa fragment
(arrowhead). The antigenic epitopes of these antibodies
have been characterized previously in detail (Brennan
and Mahoney, 2009). Thus, our data demonstrate that
the 160-kDa full-length and the truncated 65-kDa
intracellular fragment both localized to lipid rafts.
Disruption of lipid rafts led to the retention of the 65-
kDa intracellular domain of Dsg2 in the non-lipid raft
membrane fractions.
Next, we wanted to assess whether treatment with
MbCD would alter the subcellular localization of Dsg2.
Cells were ﬁxed and stained for Dsg2 (antibody
DG3.10) and Cav-1 (Figure 6). In control untreated
cells, we observed diffuse cell-surface staining for Cav-1
(Figure 6a, red) and punctate cell–cell border staining
for Dsg2 (Figure 6b, green). In response to MbCD
treatment, we observed a detachment of keratinocytes
and enhanced localization of Cav-1 to the cytoplasm
(Figure 6e). Interestingly, treatment with MbCD also
resulted in an increase in cytoplasmic staining for Dsg2.
MbCD had little effect on the cell–cell border localiza-
tion of Dsg2; however, the cell–cell contacts were no
longer contiguous. Interestingly, at the points of cell–cell
contacts, we observed an increase in colocalization of
Dsg2 and Cav-1. We surmise that the treatment with
MbCD disrupted caveolae formation, thereby releasing
Cav-1 from these specialized membrane rafts. Cav-1
may then freely associate with other desmogleins or
junctional proteins.
Disruption of Cav-1 association altered Dsg2 localization
and keratinocyte cell adhesion
Next, we wanted to determine whether disrupting the
Dsg2–Cav-1 interaction would alter Dsg2 localization
within lipid rafts by examining the effect of AP–Cav-1
on Dsg2 distribution in light versus heavy membrane
fractions following sucrose-gradient fractionation. A431
cells were treated with AP and AP–Cav-1 peptides
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Figure 3 Dsg2 associates with the Cav-1 consensus binding
peptide. (a) Sequence analysis of Dsg1–4 showing putative Cav-1-
binding sites in the inverse orientation of the consensus motif,
fXfXXXXf. f, aromatic amino acids (F, Y and W); X, any
amino acid. In bold are aromatic amino acids and underlined are
hydrophobic amino acids. (b) A431 cells were incubated with the
biotinylated AP ([(biotin)-RQPKIWFPNRRKPWKK-(OH)];
5mM) or the Cav-1 consensus binding peptide conjugated to AP
(AP–Cav-1; [(biotin)-RQPKIWFPNRRKPWKKDGIWKASFT
TFTVTKYWFYR-(OH)]; 5mM) for 2 h. Cells were lysed and
extracted in a Tx lysis buffer, and proteins were resolved over SDS–
PAGE and immunoblotted with avidin–HRP to show incorporated
biotinylated AP and AP–Cav-1. (c) Total extracted proteins were
then subjected to immunoprecipitation with the Dsg2 antibody
10D2 and protein-A/G–agarose. The precipitated products were
immunoblotted with HRP–strep-avidin. The results show that
Dsg2 associated with AP–Cav-1, but not AP alone.
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(5 mM) for 2 h. Total cellular proteins were separated
over a discontinuous sucrose gradient. Fractionated
proteins were resolved over SDS–PAGE and immuno-
blotted for Dsg2 and actin (Supplementary Figure S2).
Disrupting the interaction between Dsg2 and Cav-1 with
the Cav-1 competing antennapedia peptides partially
shifted Dsg2 out of the low-density membrane lipid raft
fractions. Furthermore, the Cav-1 competing peptides
also induced a loss of keratinocyte adhesion. After
treating A431 cells with AP or AP–Cav-1 peptides, cells
were dislodged from the petri dish using dispase. Cell
sheets were subjected to dispase-based keratinocyte
dissociation assay, showing more fragmentation after
treatment with AP–Cav-1 peptides, as compared with
control untreated or when treated with AP alone.
Shown are representative results from three separate
experiments (Supplementary Figure S3).
Proteolytic processing of Dsg2 during malignant
transformation
It was demonstrated previously that shedding of the
extracellular domain of Dsg2 protects epithelial cells
from apoptosis (Nava et al., 2007). To determine
whether the 65-kDa Dsg2 fragment observed here
resulted from ectodomain shedding, we collected condi-
tioned media from various epithelium-derived cell lines
and performed immunoblot analysis to detect the shed
fragment of Dsg2. Of the cell lines tested, the JAR
choriocarcinoma cell line showed the highest level of
Figure 4 The Cav-1 consensus binding peptide perturbs membrane localization of Dsg2. Cells were treated with dimethyl sulfoxide,
AP peptide or the AP–Cav-1 peptide for 24 h. They were then washed, ﬁxed and immunostained for Dsg2 (antibodies 6D8 and
DG3.10). Insets: Enlarged images. In response to the AP–Cav-1 peptide, but not dimethyl sulfoxide or AP peptide alone, the staining
for Dsg2 appeared more diffuse and less punctate at the cell–cell border. Nuclei counterstained with DAPI (blue).
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Dsg2 expression (Figure 7a). Cells were then grown to
conﬂuence and the conditioned medium was collected,
concentrated and immunoblotted for Dsg2. The results
showed a shed ectodomain product of approximately
95 kDa (barbed arrow), detected by 10D2, but not
DG3.10 (Figure 7b, lanes M for medium). Tx-soluble
and -insoluble fractions were prepared from JAR cells
and immunoblot analysis revealed a 65-kDa fragment
recognized by DG3.10, but not 10D2 (Figure 7b,
arrowhead).
As A431 cells showed signiﬁcantly less Dsg2 cleavage
as compared with JAR cells, we treated A431 cells with
the cytotoxic quinoline alkaloid camptothecin (10 mM)
for 6 h to induce the apoptosis and processing of many
proteins. Supernatant was collected, concentrated and
proteins were immunoblotted with a series of antibodies
against the extracellular (10D2, 10G11, Rb5, 6D8 and
Ab10) and cytoplasmic (H-145 and DG3.10) domains of
Dsg2 (Figure 7c). Treatment with camptothecin en-
hanced the ectodomain shedding of Dsg2, resulting in
an accumulation of the 95-kDa fragment, which was
recognized by antibodies to the extracellular domain but
not antibodies to the intracellular domain (Figure 7c,
– MβCD
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Figure 5 Localization of Dsg2 and Cav-1 to membrane lipid rafts.
(a) A431 cells were treated with MbCD (10mM) for 1 h and
extracted in a Tris–NaCl–EDTA buffer containing Tx. Proteins
were subjected to a discontinuous (5–35%) sucrose-gradient
separation, resolved over SDS–PAGE and immunoblotted for
Cav-1, Cav-2, Flo1, Flo2, b-Cat, g-Cat, actin, E-Cad and Dsg2. IB
revealed that Cav-1 localized predominantly to low-density
fractions 4 and 5 (top left panel), corresponding to lipid rafts.
Dsg2 was distributed through all fractions from 4 to 12. Treatment
with MbCD (10mM) for 1 h disrupted lipid rafts and shifted both
Cav-1 and Dsg2 to the more dense fractions. In addition to the 160-
kDa Dsg2 full-length protein, we observed a 65-kDa band in the
lipid raft fraction 4 (vertical arrow). Accumulation of this fragment
was enhanced and shifted to the denser fractions in the presence of
MbCD (arrowhead). We note that b-Cat, g-Cat, E-Cad and actin
fractioned to the lower, denser fractions, and remained relatively
unchanged in the presence of MbCD. (b) Proteins from fractions 4
(lipid raft fraction) and 12 (high-molecular-weight, non-raft
fraction) above were resolved over SDS–PAGE and immuno-
blotted for Dsg2 using two different antibodies, 10D2 and DG3.10.
Treatment with MbCD increased the level of the 65-kDa Dsg2
fragment as detected by DG3.10, but not 10D2.
Control + MβCD
Cav-1
Dsg2
Merge
Zoom
Figure 6 Blocking of caveolae formation disrupts cell–cell
adhesion. A431 cells were treated with DMSO (a–d) or MbCD
(e–h) for 1 h, washed, ﬁxed and subjected to IF staining for Dsg2
(green) and Cav-1 (red). Results show that blocking the formation
of caveolae with MbCD resulted in a partial loss of cell–cell
adhesion and enhanced the cytoplasmic staining of both Cav-1 and
Dsg2. Nuclear staining with DAPI in blue.
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barbed arrow). We note that the more sensitive Dsg2
antibodies, 6D8 and Ab10, detected some shed Dsg2 in
the medium of control untreated cells.
To determine whether the 65-kDa Dsg2 fragment
binds to Cav-1, we performed immunoprecipitation
followed by western blotting analysis. Camptothecin-
treated A431 cell lysate was immunoprecipitated with
Cav-1 antibodies, and the precipitated product was
immunoblotted with the antibodies Ab10 and H-145
(Figure 7d). We note here that antibody Ab10 was
raised against extracellular domain-5 (EC5) of Dsg2, the
region adjacent to the transmembrane domain (Brennan
and Mahoney, 2009). Ab10 recognized both the 95-kDa
extracellular shed product as well as the 65-kDa
membrane-spanning fragment (not shown). Immuno-
blots performed with Ab10 and H-145 detected a band
migrating at approximately 65 kDa after precipitation
for Cav-1. These ﬁndings further support our results
above that the 65-kDa Dsg2 fragment associates with
Cav-1. Our data thus far demonstrate that both the full-
length 160-kDa and the truncated 65-kDa intracellular
fragment localize to lipid rafts, and interact with Cav-1.
Furthermore, although Cav-1 can bind to the full-length
protein, it binds predominantly to the 65-kDa fragment.
Disruption of lipid rafts may lead to the re-localization
of this truncated 65-kDa product.
Finally, we wanted to determine whether Dsg2
undergoes proteolytic processing during skin cancer
development, in vivo. For these experiments, we used a
transgenic mouse line that was recently established in
our laboratory, where Flag-tagged Dsg2 is expressed
under the control of the involucrin (Inv) promoter
(Brennan et al., 2007). Inv-Dsg2 transgenic and wild-
type (WT) control littermates were subjected to DMBA
(7,12-dimethyl-benz[a]anthracene)/TPA (12-O-tetrade-
canoylphorbol-13-acetate)-induced skin tumor develop-
ment, as described previously, for 8 weeks (Brennan
et al., 2007). Skin tumor tissues were extracted in
Laemmli sample buffer, and proteins were resolved by
SDS–PAGE and immunoblotted using a polyclonal
anti-Flag antibody. We detected the 160-kDa Dsg2–
Flag protein in the skin and tumors from transgenic, but
not in WT mice (Figure 8a, arrow). Interestingly,
although the level of full-length Dsg2 in the tumors of
transgenic mice was comparable to unaffected skin in
these mice, the level of proteolytic processing of Dsg2
protein was signiﬁcantly enhanced in the tumor
tissues. Among the many unique bands ranging from
the 160-kDa full-length Dsg2 protein to a small 40-kDa
fragment detected by the Flag antibody, we observed a
major band of approximately 65 kDa (Figure 8a, arrow-
head).
Several older Inv-Dsg2 transgenic mice developed
spontaneous skin tumors (not shown). Thus far, none of
the WT littermates have developed tumors, as expected
of the tumor-resistant C57Bl6 background. To further
conﬁrm the proteolytic processing of Dsg2 in tumor
tissues, we extracted proteins from spontaneously
derived tumors and tumors derived after DMBA/TPA
treatment. Again, proteins were resolved over SDS–
PAGE for western blotting, but this time, using a
monoclonal anti-Flag antibody (Figure 8b). Immuno-
blots showed that, in addition to the 160-kDa full-length
protein (arrow), we observed a prominent 65-kDa band
(arrowhead). Thus, we propose that the 65-kDa band
observed here maybe the membrane-spanning intracel-
lular Dsg2 product resulting from ectodomain shedding,
and that generation of this product may have a role in
tumor progression. Although we cannot rule out the
in vitro proteolytic processing of Dsg2 during tissue
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Figure 7 Cav-1 associates with the processed 65-kDa Dsg2
fragment. (a) Cultured HaCaT (H), A431 (A) and JAR cells (J)
were grown to conﬂuence, lysed in Laemmli buffer and immuno-
blotted for Dsg1, Dsg2, Dsg3 and Dsg4. The blots were reprobed
with actin antibodies for equal loading. (b) Medium (M) was
collected from JAR cells and concentrated. Cells were then
extracted into Tx-soluble (S) and -insoluble (I) fractions. All
protein fractions were processed for IB with 10D2 and DG3.10. A
shed product of approximately 95 kDa was detected in the medium
using 10D2 but not DG3.10. A 65-kDa product was detected in the
Tx-soluble and -insoluble fractions with DG3.10, but not 10D2. (c)
A431 cells were treated with camptothecin (5mM) for 6 h. Medium
was collected, concentrated and immunoblotted to show enhanced
Dsg2 ectodomain shedding as detected by antibodies to the
ectodomain of Dsg2 (10D2, 10G11, Rb5, 6D8 and Ab10) but not
antibodies to the cytoplasmic domain of Dsg2 (H-145 and
DG3.10). (d) A431 cells were treated with camptothecin and then
lysed in Tx lysis buffer. Cellular proteins were subjected to
immunoprecipitation using Cav-1 antibodies and protein-A/G–
agarose. Bound proteins were immunoblotted with the antibodies
Ab10 and H-145 to show a protein of approximately 65 kDa
recognized by the Dsg2 antibodies. CPT, camptothecin; I,
Tx-insoluble; MbCD, methyl-b-cyclodextran; M, medium; S,
Tx-soluble; Tx, Triton X-100.
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prepping, we immunoblotted the same samples for Dsg1
showing the lack of processing of Dsg1 in these same
tumor samples. If there was in vitro processing, we
suspect that Dsg1 would also be degraded similar to
Dsg2. We note here that, owing to lack of spontaneous
tumors in WT mice, we were unable to assess the
endogenous level of Dsg2.
Discussion
During malignant transformation, cell–cell contacts are
often reorganized, and desmosome assembly and
stability are altered. However, there is conﬂicting
evidence as to what roles desmosomal adhesion and/or
desmosomal components have during cancer develop-
ment and progression. We recently showed a correlation
between Dsg2 expression and skin tumor progression,
where we observed aberrant localization of Dsg2 in the
cytoplasm and nuclei (Brennan and Mahoney, 2009). In
the present study, we demonstrate colocalization of
Dsg2 with Cav-1, which may have implications in the
role of Dsg2 in carcinogenesis. We show that Dsg2
contains the necessary consensus-binding motifs to
interact directly with the Cav-1 scaffolding domain.
We believe that deﬁning the interaction between Dsg2
and Cav-1 is important, as it may have an impact on cell
adhesion (through regulation of turnover/dynamics),
and possibly signaling, both of which could contribute
to tumor progression.
We propose the following model of desmosome
homeostasis (Figure 9) whereby desmosomes actively
undergo assembly and disassembly. Junctional proteins
such as desmogleins are subjected to dynamic turnover
through a caveolae/lipid raft-dependent pathway. We
show here that Dsg2 is proteolytically processed,
resulting in a 95-kDa ectodomain shed product and a
65-kDa membrane-spanning fragment. The full-length
and the truncated intracellular Dsg2 fragment associate
with Cav-1 and are mobilized into membrane lipid rafts,
where they are most likely fated for internalization and
degradation. Altering the Dsg2–Cav-1 interaction,
either by disrupting caveolae/lipid raft formation or
with Cav-1-speciﬁc inhibitor peptides, leads to the
retention of the 65-kDa fragment (Figure 5). We
speculate that accumulation of this truncated Dsg2
fragment may disturb desmosome assembly and disrupt
cell–cell adhesion.
The loss of cell–cell adhesion observed in our study is
reminiscent of that reported using transgenic mice
expressing NH2-terminally truncated Dsg3, which
resulted in an accumulation of Dsg3DN, and disrupted
desmosome assembly (Allen et al., 1996). If proteolytic
processing and endocytic turnover of desmogleins are
important for maintenance of desmosome dynamics,
then results from studies using chimeric proteins, such as
E-cadherin with Dsg3 (Andl and Stanley, 2001) or
connexin with Dsg1 (Troyanovsky et al., 1993), may
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Figure 8 Proteolytic processing of Dsg2 in skin tumors. (a)
Representative examples of skin tumor developing in a WT and
Inv-Dsg2 (Tg) mouse after 8 weeks of DMBA/TPA treatment.
Tissues were lysed in Laemmli buffer and immunoblotted using a
Flag polyclonal antibody, showing multiple lower molecular weight
protein fragments of Dsg2 in the Tg tumor. Unique bands
estimated approximately in kDa: 160, 120, 100, 80, 75, 65, 55, 50,
45 and 40. Similar results were observed in two other sets of WT
and Tg littermates. Blotting for actin shows equal loading. (b)
Proteolytic processing of Dsg2 was also observed in spontaneous
tumors developed from aged Inv-Dsg2 Tg mice. DMBA/TPA-
induced or spontaneously developed tumor tissues from Inv-Dsg2
transgenic mice were extracted in Tx lysis buffer. Tx-soluble and -
insoluble proteins were resolved over SDS–PAGE and immuno-
blotted for Dsg2–Flag (monoclonal antibody), Dsg1 and actin (for
equal loading). The results show the presence of the 65-kDa Dsg2
fragment in the Tx-insoluble fractions of both spontaneous and
chemical-induced skin tumors in Inv-Dsg2 Tg mice. The Dsg1
antibody only detected the full-length product of approximately
160 kDa. DMBA 7,12-dimethyl-benz[a]anthracene; I, Tx-insoluble;
S, Tx-soluble; Spon, spontaneous; TPA, phorbol ester 12-O-
tetradecanoylphorbol-13-acetate; Tx, Triton X-100.
Loss of Caveolae
Caveolae
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Caveolins Signaling Molecules
Internalization/Degradation
Figure 9 A schematic diagram depicting the roles of Cav-1 and
caveolae in desmoglein trafﬁcking and desmosome homeostasis.
Full-length as well as cleaved desmogleins associate with Cav-1 in
the caveolae, and are most likely fated for internalization and
recycling. This model offers a mechanism by which desmogleins
can be cleared from the plasma membrane and in the process
possibly activate mitogenic cell signaling through their interaction
with Cav-1. Loss of Cav-1 in cancer allows the accumulation of the
proteolytic fragments, which may affect cell–cell adhesion.
Furthermore, loss of Cav-1 may also result in abnormal signaling.
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also reﬂect the loss of appropriate ectodomain shedding
and desmoglein recycling.
Dsg2 was recently identiﬁed as a proteolytic target of
ADAM17 (Bech-Serra et al., 2006; Santiago-Josefat
et al., 2007; Klessner et al., 2009), a member of the
sheddase family. ADAMs are a class of enzymes
involved in the ectodomain shedding of transmembrane
proteins involved in receptor activation (Kenny and
Bissell, 2007). ADAM17 cleaves Dsg2 in the region
adjacent to the transmembrane domain, which would
result in a shed ectodomain of approximately 95 kDa
and an intracellular product of approximately 65 kDa.
We believe the 65-kDa Dsg2 fragment is membrane-
spanning, as we show that (1) antibodies recognizing
extracellular epitopes detected this 95-kDa band,
whereas antibodies raised against intracellular epitopes
recognized the 65-kDa fragment, and (2) our polyclonal
antibody Ab10, raised against the extracellular mem-
brane-anchoring (EC5) domain, detected both the shed
ectodomain and the membrane-bound fragment. Thus,
if the cleavage site is within the EC5 domain, then Ab10
may contain antibodies recognizing the shed ectodo-
main, as well as antibodies to the membrane-spanning
cytoplasmic domain.
Further supporting our hypothesis on the importance
of Dsg2 proteolytic processing, in epithelial cancers
epidermal growth factor receptor is often deregulated,
and inhibition of epidermal growth factor receptor
function promotes Dsg2 assembly into desmosomes
(Lorch et al., 2007). Furthermore, this inhibition occurs
at least in part through attenuation of ADAM-
dependent cleavage of Dsg2, the latter of which
contributes to its endocytic turnover (Klessner et al.,
2009). At the onset of apoptosis in intestinal epithelial
cells, Dsg2 is cleaved by cysteine proteases, and down-
regulation of Dsg2 by small interfering RNA protects
cells from apoptosis (Nava et al., 2007). Dsg2 has also
been identiﬁed as a proteolytic target of caspase-3
(Cirillo et al., 2008), one of many caspases that comprise
a family of proteins known to have critical roles in
maintaining the cellular homeostasis between growth/
survival and apoptosis (Rupinder et al., 2007; Denault
and Salvesen, 2008). As mentioned above, ADAM17 is
involved in the proteolytic processing of Dsg2.
ADAM17 has been implicated in the development of
cancer, and is being investigated as a possible target for
anticancer therapies (Arribas et al., 2006). We are
currently investigating the biological activity of the shed
extracellular domain of Dsg2.
We reported previously that Dsg2 modulates cell
growth and survival signaling pathways by demonstrat-
ing that ectopic expression of Dsg2 enhances epidermal
proliferation and also increases susceptibility to two-
step chemical-induced skin carcinogenesis (Brennan
et al., 2007). In this report, we demonstrate enhanced
expression and proteolytic processing of Dsg2 during
skin tumor progression, which may contribute to the
malignant phenotype, possibly through a caveolin-
mediated pathway. This is a signiﬁcant ﬁnding, as
Cav-1 expression has been linked to many epithelium-
derived cancers, and it has been shown that loss of
Cav-1 function has a signiﬁcant role in tumor initiation.
It is proposed that Cav-1 binds to and inhibits kinases
involved in mitogenic signaling pathways (Lajoie and
Nabi, 2010). In many cancers, caveolins are down-
regulated and the loss of caveolae may release these
signaling molecules to activate mitogenic pathways.
Interestingly, Cav-1 knockout mice display normal skin
morphology, suggesting that, in addition to caveolin
ablation, these mice may require an appropriate
‘oncogenic’ stimulus. We propose that during skin
tumor development, the up-regulation of an oncogenic
stimulus such as Dsg2 and the concomitant down-
regulation of caveolins may provide the necessary
stimuli for cell proliferation, signaling activation and
malignant transformation. Furthermore, downregula-
tion of caveolins may result in an accumulation of the
truncated Dsg2 fragment, which could potentially
disrupt cell–cell adhesion, a process crucial for tumor
cell migration and egression.
Materials and methods
Antibodies
Antibodies from our laboratories were Ab10 (1:10 000
(immunoblotting (IB)), 6D8 (1:10 IF and 1:100 (IB)), 10D2
(1:10 (IF) and 1:100 (IB)), 6F9 b-catenin (1:1000 (IB)) and
11E4 g-catenin (1:500 (IB)). The commercially purchased
primary antibodies were Cav-1 (1:200 (IF) and 1:1000 (IB))
and H-145 (1:1000 (IB)) (from Santa Cruz Biotechnology
(Santa Cruz, CA, USA)); E-cadherin (1:2500 (IB)), Cav-2
(1:1000 (IB)), ﬂotillin-1 (1:500 (IB)) and ﬂotillin-2 (1:5000 (IB))
(from BD Transduction Labs (Franklin Lakes, NJ, USA));
Flag M2 (1:1000 (IF) and 1:1000 (IB)) and Flag pAb (1:1000
(IB)) (from Sigma (St Louis, MO, USA)); DG3.10 (1:200 (IF)
and 1:1000 (IB)) (from RDI Corp (Henderson, NV, USA));
b-actin (1:100 000 (IB)) (from Calbiochem (San Diego, CA,
USA)); and GST (1:2500 (IB)) (from GE Healthcare (Piscat-
away, NJ, USA)). The secondary antibodies included were
Alexa Fluor-594- and Alexa Fluor-488-conjugated (1:400;
Molecular probes, Eugene, OR, USA) and HRP-conjugated
(1:5000; Jackson labs, Bar Harbor, ME, USA).
GST fusion proteins
cDNA encoding the intracellular domains of Dsg1 (1921–
3845) and Dsg2 (1911–3516) were generated by PCR and
inserted by in-frame cloning into the vector PGEX4T-1 (GE
Healthcare) at BamHI and SalI restriction sites for Dsg1 and
at BamHI and NotI restriction sites for Dsg2. GST fusion
proteins were produced in BL21 Escherichia coli cells
after induction with isopropyl-b-D-thiogalactoside (1mM) and
puriﬁed as described previously in detail (Brennan and
Mahoney, 2009).
Cell culture, drug treatment and protein extraction
A431, HaCaT and JAR cells (ATCC, Manassas, VA, USA)
were cultured in Dulbecco’s modiﬁed Eagle’s medium medium
supplemented with penicillin/streptomycin and 10% fetal
bovine serum. To detect shedding of the Dsg2 ectodomain,
medium was collected after 2 days in Dulbecco’s modiﬁed
Eagle’s medium without fetal bovine serum and concentrated
by 10-fold using Amicon Ultra concentrators (Millipore Corp.,
Billerica, MA, USA). To enhance shedding, A431 cells were
treated with camptothecin (10mM) in serum-free medium for
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5–6 h. Cells were lysed in Laemmli buffer. For Tx-soluble
proteins, cells were incubated on ice for 20min in a 1% Tx-
containing buffer (50mM Tris–HCl (pH 7.5), 150mM NaCl
and 5mM EDTA), complete with protease inhibitors (Roche
Diagnostics, Indianapolis, IN, USA) and phosphatase inhibi-
tors (Sigma). The insoluble pellet was resuspended in Laemmli
buffer for Tx-insoluble proteins.
To disrupt lipid microdomains, cells were treated with
MbCD (10mM) or ﬁlipin (5 mg/ml) (Sigma). MbCD and ﬁlipin
have been used extensively as the standard methods to disrupt
raft-like microdomains. We are aware that there are limita-
tions to the use of MbCD because it may affect both caveolin
levels and caveolae structures, and may target both caveolar
and non-caveolar rafts. However, the key point is that Dsg2
can be localized to lipid rafts and can interact with Cavs.
Dispase-based keratinocyte dissociation assay
A431 cells were grown in six-well culture dishes to conﬂuence
in Dulbecco’s modiﬁed Eagle’s medium þ 10% fetal calf
serum and then treated with 5mM AP or AP–Cav-1 peptides in
serum-free medium for 2 h. Cells were washed with Hank’s
Balanced Salt Solution and incubated with dispase-I (BD
Biosciences, San Diego, CA, USA) for 20–30min. The lifted
cell sheets were subjected to dispase-based dissociation assay
by pipetting ﬁve times by using a 1-ml pipette. Cell fragments
were ﬁxed in 10% formalin solution and stained with crystal
violet.
IB, immunohistochemistry and immunoprecipitation
IB was performed with 2–25mg of protein in each lane resolved
over 5 or 12% SDS–PAGE (Bio-Rad Labs, Hercules, CA,
USA) as described previously in detail (Brennan et al., 2007).
Signals were detected by chemiluminescence (ECL; GE
Healthcare). For western blotting of biotinylated AP and
AP–Cav-1 peptides, immunoprecipated proteins were resolved
over a 20% SDS–PAGE Tricine gel (Bio-Rad Labs) and
electrotransferred for 30min at a constant 80V to a
polyvinylidene diﬂuoride membrane. Non-speciﬁc sites were
blocked in Superblock (Thermo Scientiﬁc, Waltham, MA,
USA); membranes were then incubated with strept-avidin–
HRP (1:1000; Thermo Scientiﬁc) and immunoreactive bands
visualized by chemiluminescence.
For IF, OCT-ﬁxed human skin sections (5mm) were prepared
as described previously (Brennan et al., 2007). Brieﬂy, tissue
sections were ﬁxed in 100% methanol and permeabilized in 1%
Tx in phosphate-buffered saline. Nuclei were stained with 40,6-
diamidino-2-phenylindole (DAPI) (Sigma) prior to mounting
for viewing. Similar steps were performed for immunostaining
of cultured cells. Fluorescent images were acquired by using a
Hamamatsu monochromatic digital camera (Phase 3 Imaging
Systems; Glen Mills, PA, USA; C4742-95), and analyzed by
using the Image Pro 6.1 imaging software (Media Cybernetics,
Bethesda, MD, USA). Confocal images were obtained by using
a Zeiss LSM 510 META confocal scanning microscope system
and software (Bioimaging Facility, Thomas Jefferson Uni-
versity, Philadelphia, PA, USA).
For immunoprecipitation, cells were solubilized in a buffer
containing 50mM Tris–HCl (pH 7.5), 150mM NaCl, 5mM
EDTA, 1% Tx, 1mM phenylmethylsulfonyl ﬂuoride and
protease and phosphatase inhibitors. Samples were pre-cleared
with mouse or rabbit IgG agarose (25 ml; Sigma). Lysates were
then incubated in antibodies (0.3ml 6D8 or 5 mg/ml anti-
Cav-1) and protein-A/G–agarose (30 ml; Pierce Biotechnol-
ogy). Immune complexes were washed with 1%Tx-phosphate-
buffered saline and suspended in Laemmli buffer for IB.
Isolation of caveolin-rich membrane fractions
Cells were washed twice with ice-cold PBS and scraped into
TNE buffer (25mM Tris–HCl (pH 7.5), 150mM NaCl and 5mM
EDTA) containing 1% Tx, phenylmethylsulfonyl ﬂuoride,
protease and phosphatase inhibitors (Galbiati et al., 2000).
Cells were disrupted by using a loose-ﬁtting Dounce Homo-
genizer (20 strokes), and sucrose concentration was brought to
45% by mixing 2ml of cell lysates with equal volume of 90%
sucrose. The mixture was placed at the bottom of an
ultracentrifuge tube, and a discontinuous sucrose gradient was
formed above the cell mixture by over-laying 4ml each of 35%
and 5% sucrose. The samples were centrifuged at 40 000 r.p.m.
for 16–20 h in an SW41 rotor (Beckman Instruments, Fullerton,
CA, USA). Twelve 1-ml fractions were collected from the top.
Skin tumor induction and tissue extraction
We recently established transgenic mice expressing Dsg2 in the
differentiating layers of the epidermis under the control of the
Inv promoter (Inv-Dsg2) (Brennan et al., 2007). Brieﬂy mouse
Dsg2-Flag cDNA was subcloned into the pH3700-pL2
parental vector epitope at the NotI restriction site downstream
from the Inv promoter. The genotyping and characterization
of the transgenic mice have been described previously in detail
(Brennan et al., 2007). Adult WT and Inv-Dsg2 transgenic
mice (6–8 weeks old) were treated once with DMBA (400 nmol
in 200ml of acetone) followed by TPA (17 nmol in 200 ml of
acetone) twice weekly, as described previously (Brennan et al.,
2007). Mouse back skin and tumors were processed in
radioimmunoprecipitation assay buffer (50mM Tris–HCl (pH
7.5), 150mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate,
0.1% SDS and protease inhibitors).
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